Stay updated on HBI-8000 Combo with Nivolumab in Solid Tumors Clinical Trial

Sign up to get notified when there's something new on the HBI-8000 Combo with Nivolumab in Solid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the HBI-8000 Combo with Nivolumab in Solid Tumors Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:38:29.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the study details of a Phase 1b/2 clinical trial evaluating the safety and efficacy of HBI-8000 in combination with Nivolumab in patients with advanced solid tumors including Melanoma, Renal Cell Carcinoma, and Non-Small Cell Lung Cancer.
    Difference
    0.1%
    Check dated 2024-06-06T14:33:13.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for study participants, specifying that only adults aged 18 and older with certain health conditions and prior treatments are eligible. The new criteria also outline specific health and laboratory requirements, as well as exclusion factors for potential participants.
    Difference
    34%
    Check dated 2024-05-22T21:25:44.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:48:21.000Z thumbnail image

Stay in the know with updates to HBI-8000 Combo with Nivolumab in Solid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the HBI-8000 Combo with Nivolumab in Solid Tumors Clinical Trial page.